| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 220.00 |
| 52 Week High | SEK 221.00 |
| 52 Week Low | SEK 169.00 |
| Beta | 1.78 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -58.06% |
| 5 Year Change | 12.94% |
| Change since IPO | 61.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| VITRS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | 0.4% |
| 1Y | n/a | -17.7% | 7.6% |
Return vs Industry: Insufficient data to determine how VITRS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how VITRS performed against the UK Market.
Price Volatility
| VITRS volatility | |
|---|---|
| VITRS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.9% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: VITRS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine VITRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,111 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems.
Vitrolife AB (publ) Fundamentals Summary
| VITRS fundamental statistics | |
|---|---|
| Market cap | SEK 31.33b |
| Earnings (TTM) | -SEK 3.80b |
| Revenue (TTM) | SEK 3.56b |
8.8x
P/S Ratio-8.2x
P/E RatioIs VITRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VITRS income statement (TTM) | |
|---|---|
| Revenue | SEK 3.56b |
| Cost of Revenue | SEK 1.49b |
| Gross Profit | SEK 2.07b |
| Other Expenses | SEK 5.87b |
| Earnings | -SEK 3.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | -28.10 |
| Gross Margin | 58.17% |
| Net Profit Margin | -107.03% |
| Debt/Equity Ratio | 14.6% |
How did VITRS perform over the long term?
See historical performance and comparison